A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial
Stereotactic ablative body radiotherapy (SABR) is an emerging treatment alternative for patients with localized low and intermediate risk prostate cancer patients. As already explored by some authors in the co... (Source: Radiation Oncology)
Source: Radiation Oncology - May 3, 2024 Category: Cancer & Oncology Authors: Almudena Zapatero, Pablo Castro, Mar ía Roch, Pablo Rodríguez Carnero, Sara Carroceda, Alexandra Elena Stoica Rosciupchin, Sergio Honorato Hernández, Leopoldo Cogorno, Alfonso Gómez Iturriaga and David Büchser García Tags: Study Protocol Source Type: research
A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer
(Source: World Journal of Urology)
Source: World Journal of Urology - May 3, 2024 Category: Urology & Nephrology Source Type: research
Curvilinear catheter implantation in HDR prostate brachytherapy: feasibility study
CONCLUSION: This work demonstrates the feasibility of using tendon-driven active curvilinear catheter implantation in prostate to improve the outcomes of HDR-BT via improved radiation dose distribution to the prostate and reduced toxicity to the OARs.PMID:38695825 | DOI:10.1002/mp.17113 (Source: Health Physics)
Source: Health Physics - May 2, 2024 Category: Physics Authors: Blayton Padasdao Rex Imanaka Tarun K Podder Bardia Konh Source Type: research
Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status
CONCLUSIONS: The findings highlight the potentially worse prognosis in patients with pgMIBC compared to dnMIBC, even with the modern use of NAC. The study emphasizes the importance of careful patient counseling, further classification of patients for treatment selection, and the consideration of additional or innovative systemic therapies for pgMIBC.PMID:38697874 | DOI:10.1016/j.urolonc.2024.04.020 (Source: Urologic Oncology)
Source: Urologic Oncology - May 2, 2024 Category: Urology & Nephrology Authors: Leilei Xia Anosh Dadabhoy Erika L Wood Sejal V Mehta Daniel S Roberson Thomas J Guzzo Trinity J Bivalacqua Siamak Daneshmand Source Type: research
Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status
CONCLUSIONS: The findings highlight the potentially worse prognosis in patients with pgMIBC compared to dnMIBC, even with the modern use of NAC. The study emphasizes the importance of careful patient counseling, further classification of patients for treatment selection, and the consideration of additional or innovative systemic therapies for pgMIBC.PMID:38697874 | DOI:10.1016/j.urolonc.2024.04.020 (Source: Urologic Oncology)
Source: Urologic Oncology - May 2, 2024 Category: Urology & Nephrology Authors: Leilei Xia Anosh Dadabhoy Erika L Wood Sejal V Mehta Daniel S Roberson Thomas J Guzzo Trinity J Bivalacqua Siamak Daneshmand Source Type: research
Identification of a pyroptosis-immune-related lncRNA signature for prognostic and immune landscape prediction in bladder cancer patients
ConclusionThis novel signature provides a theoretical basis for cancer immunology and chemotherapy, which might help develop individualized therapy. (Source: Hormones and Cancer)
Source: Hormones and Cancer - May 2, 2024 Category: Cancer & Oncology Source Type: research
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
World J Hepatol. 2024 Apr 27;16(4):490-493. doi: 10.4254/wjh.v16.i4.490.ABSTRACTCancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mec...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Mohamed Wishahi Source Type: research
Autoimmune diseases and the risk of bladder cancer: A Mendelian randomization analysis
CONCLUSION: This study provides evidence of a causal relationship between AIDs and BC risk at the genetic level, confirming a causal relationship between RA and MS in increasing the risk of BC.PMID:38692170 | DOI:10.1016/j.jaut.2024.103231 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - May 1, 2024 Category: Allergy & Immunology Authors: Jun Li Cui Cheng Jiajun Zhang Source Type: research
